- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Circulating tumor cells in breast cancer: clinical validity and utility ; volume:10 ; number:1 ; day:29 ; month:11 ; year:2024 ; pages:1-10 ; date:12.2024
npj Breast cancer ; 10, Heft 1 (29.11.2024), 1-10, 12.2024
- Urheber
-
Thomas-Bonafos, Thibault
Pierga, Jean Yves
Bidard, François-Clément
Cabel, Luc
Kiavue, Nicolas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-024-00706-7
- URN
-
urn:nbn:de:101:1-2502142104510.759383093842
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Thomas-Bonafos, Thibault
- Pierga, Jean Yves
- Bidard, François-Clément
- Cabel, Luc
- Kiavue, Nicolas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Minimal residual disease and circulating tumor cells in breast cancer
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Minimal residual disease and circulating tumor cells in breast cancer
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Minimal residual disease and circulating tumor cells in breast cancer
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors